Join the Class Action Suit for Unicycive Therapeutics Shareholders
The Gross Law Firm is reaching out to shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) regarding a class action lawsuit. If you have acquired shares during the specified class period, it is crucial that you understand your rights and the steps available for potential recovery of your investments.
Engagement for Shareholders
We encourage all shareholders who purchased shares of UNCY from March 29, 2024, to June 27, 2025, to consult with us about becoming a lead plaintiff in this case. Participation as a lead plaintiff is not necessary for recovery; all affected parties should consider registering their interest.
Class Period Details
The class period encompasses transactions made in the specified dates. Any shareholder who bought into UNCY during this timeframe may be eligible for compensation based on the outcomes of the lawsuit.
Allegations Against the Company
The complaint implies that Unicycive made several statements that were materially misleading or false during the class period. Specifically, it alleges that the company exaggerated its readiness to meet the FDA's manufacturing compliance criteria and overstated the prospects of its oxylanthanum carbonate new drug application.
As a result, public statements made by Unicycive may have contributed to an artificial inflation of the stock price, leading to investor losses when the truth came to light.
Important Deadlines
October 14, 2025, marks a crucial deadline for shareholders interested in registering for this class action. Delaying could result in missing out on potential recovery opportunities. Make sure to submit your information promptly to ensure your eligibility.
Participation Details for Affected Investors
Upon registering your involvement as a shareholder during the mentioned timeframe, you’ll gain access to a portfolio monitoring service. This service provides regular updates throughout the life of the case, keeping you informed of its progress. Remember, there's no cost or obligation required to join this class action suit.
Why Choose The Gross Law Firm?
The Gross Law Firm stands as a reputable advocate for investors, with a commitment to protecting rights against deceitful business practices. The firm aims to hold corporations accountable for non-compliance with ethical standards and fraudulent actions that harm investors. With a history of fighting for fairness in the market, we are dedicated to progressing your case effectively.
Contact Information for Assistance
For shareholders seeking guidance or wishing to participate in the forthcoming class action, please feel free to reach out:
The Gross Law Firm
15 West 38th Street, 12th Floor
New York, NY 10018
Email: [email protected]
Phone: (646) 453-8903
Frequently Asked Questions
What is the class period for the Unicycive Therapeutics lawsuit?
The class period ranges from March 29, 2024, to June 27, 2025.
How can I participate in the class action suit?
Shareholders can register their information with The Gross Law Firm to be included in the class action lawsuit.
Do I need to be a lead plaintiff to join?
No, appointment as a lead plaintiff is not necessary for recovering losses; all shareholders during the class period may participate.
Is there a cost to participate?
No, there is no cost or obligation to join the class action lawsuit.
Why should I choose The Gross Law Firm?
The Gross Law Firm is nationally recognized for protecting investors' rights and has a proven track record in class action lawsuits.
